Influenza vaccine uptake in adults aged 50-64 years: Policy and practice in England 2003/2004

被引:6
作者
Joseph, C
Elgohari, S
Nichols, T
Verlander, N
机构
[1] Hlth Protect Agcy Ctr Infect, Resp Dis Dept, London NW9 5EQ, England
[2] Hlth Protect Agcy Ctr Infect, State Modelling & Econ Dept, London NW9 5EQ, England
关键词
influenza; immunisation; vaccine uptake;
D O I
10.1016/j.vaccine.2005.10.024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A small national study was carried out in England in 2003/2004 to ascertain the views of primary care trusts (PCTs) and general practitioners (GPs) on whether influenza immunisation should be extended to all people aged 50-64 years from the current recommendation of 65 years or more. Results showed that as many primary care trusts would be in favour, as would not be in favour. A similarly divided view was expressed by general practitioners. Vaccine uptake rates for high-risk (HR) and low-risk (LR) adults aged 50-64 years in the study population were higher in those practices where the GP was in favour of a more inclusive policy of offering flu vaccine to all persons aged 50 years or more, compared with those that did not favour this policy (60% versus 54% HR (p = 0.02) and 16% versus 11% LR (p = 0.02)). Higher rates of vaccine uptake for low-risk patients aged 50-64 years were also reported from practices where GPs perceived a greater health benefit of immunisation for this age group. Although policy for recommending vaccine to all patients aged 50 years or more is established elsewhere, opinion on whether such a policy should be adopted in England is currently divided amongst those providing local health services. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1786 / 1791
页数:6
相关论文
共 48 条
  • [21] Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004
    Herrera, Guillermo A.
    Iwane, Marika K.
    Cortese, Margaret
    Brown, Cedric
    Gershman, Ken
    Shupe, Alyson
    Averhoff, Francisco
    Chaves, Sandra S.
    Gargiullo, Paul
    Bridges, Carolyn B.
    [J]. VACCINE, 2007, 25 (01) : 154 - 160
  • [22] Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old
    Sundaram, Maria E.
    Talbot, H. Keipp
    Zhu, Yuwei
    Griffin, Marie R.
    Spencer, Sarah
    Shay, David K.
    Coleman, Laura A.
    [J]. VACCINE, 2013, 31 (16) : 2057 - 2061
  • [23] Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older
    Kerzner, Boris
    Murray, Alexander V.
    Cheng, Eric
    Ifle, Rudy
    Harvey, Peter R.
    Tomlinson, Mark
    Barben, Julie L.
    Rarrick, Kimberly
    Stek, Jon E.
    Chung, Mi-Ok
    Schoedel, Florian P.
    Wang, William W. B.
    Xu, Jin
    Chan, Ivan S. F.
    Silber, Jeffrey L.
    Schlienger, Katia
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (10) : 1499 - 1507
  • [24] Influenza and pneumococcal vaccine coverage among persons aged over 65 years in Poland, 2004-2007
    Nitsch-Osuch, Aneta
    Wardyn, Kazimierz A.
    [J]. FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2009, 11 (03) : 444 - 446
  • [25] Seasonal Influenza Vaccine Effectiveness in Persons Aged 15-64 Years: A Systematic Review and Meta-Analysis
    Martins, Joao Paulo
    Santos, Marlene
    Martins, Andre
    Felgueiras, Miguel
    Santos, Rui
    [J]. VACCINES, 2023, 11 (08)
  • [26] Influenza vaccine uptake in the elderly: results from a rapid assessment of the effectiveness of new government policy in England for the winters 2000/2001 and 2001/2002
    Joseph, C
    Goddard, N
    [J]. VACCINE, 2003, 21 (11-12) : 1137 - 1148
  • [27] Intanza® 15 μg Intradermal Seasonal Influenza Vaccine in Older Adults (Aged ≥60 Years)Profile Report
    Sean T. Duggan
    Greg L. Plosker
    [J]. BioDrugs, 2010, 24 : 407 - 409
  • [28] Understanding the Global Burden of Influenza in Adults Aged 18–64 years: A Systematic Literature Review from 2012 to 2022
    Farzaneh Maleki
    Verna Welch
    Santiago M. C. Lopez
    Alejandro Cane
    Jakob Langer
    Ashley Enstone
    Kristen Markus
    Olivia Wright
    Nicole Hewitt
    Isabelle Whittle
    [J]. Advances in Therapy, 2023, 40 : 4166 - 4188
  • [29] Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain
    Perez-Rubio, Alberto
    Flores, Roberto
    Aragon, Jesus Ruiz
    Sanchez, Javier
    Marquez-Pelaez, Sergio
    Alvarez, Piedad
    Muriel, Andres Osorio
    Mould-Quevedo, Joaquin
    [J]. VACCINES, 2025, 13 (03)
  • [30] Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age
    Gorse, Geoffrey J.
    Falsey, Ann R.
    Fling, John A.
    Poling, Terry L.
    Strout, Cynthia B.
    Tsang, Peter H.
    [J]. VACCINE, 2013, 31 (19) : 2358 - 2365